 LEXINGTON, Mass.--BUSINESS WIRE--Frequency Therapeutics, Inc. Nasdaq: FREQ, a clinical-stage biotechnology company focused on harnessing the bodys innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the second quarter ended June 30, 2021. We have made important progress in our efforts to advance FX-322, our lead program for SNHL, toward its next step in clinical development. We are now comp 